The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: a systematic review
Author:
Affiliation:
1. Peninsula Technology Assessment Group, Exeter, UK
2. Southampton Health Technology Assessments Centre, Wessex Institute for Health Research and Development, Southampton, UK
Funder
Health Technology Assessment programme
Publisher
National Institute for Health Research
Subject
Health Policy
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Cost-Utility Analysis of Dasatinib and Nilotinib in Patients With Chronic Myeloid Leukemia Refractory to First-Line Treatment With Imatinib in Thailand;Clinical Therapeutics;2014-04
2. Comparative effectiveness research: a view from the other side of the pond;Journal of Comparative Effectiveness Research;2012-05
3. Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib – a Swedish model application;Acta Oncologica;2010-07-12
4. Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia;Expert Review of Pharmacoeconomics & Outcomes Research;2009-04
5. Distorções causadas pelas ações judiciais à política de medicamentos no Brasil;Revista de Saúde Pública;2007-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3